Abstracts tagged "arthritis management and biologic response modifiers"

Abstract Number: 14 • 2016 ACR/ARHP Annual Meeting
Failure Predictors to Anti-Tumor Necrosis Antagonists in Patients with Chronic Arthritis: Results of a National Registry Biobadasar
Maria Jezabel Haye Salinas¹, Soledad Retamozo², Alejandro Alvarellos³, Francisco Caeiro⁴, Juan Pablo Pirola⁴, Diego Baenas¹, María Celina de La Vega⁵, Gustavo Casado⁶, Gimena Gomez⁷, Javier Roberti⁸, Osvaldo Luis Cerda⁹, Ignacio Javier Gandino¹⁰, Ana Quinteros¹¹, Ida Exeni^6,12, Juan Manuel Bande¹³, Juan Carlos Barreira¹⁴, Carla Gobbi¹⁵, Analia Alvarez¹⁶, Amelia Granel¹⁷, Alejandra Peluzzon¹⁸, Ana Capuccio¹⁹, Romina Nieto²⁰, Rossana Quintana²¹, Eduardo Mussano²², Santiago Scarafia²³, Carolina Costi²⁴, Mercedes De La Sota²⁵, Monica Patricia Diaz²⁶, Edson Javier Velozo²⁷, Santiago Aguero²⁸, Cristina Battagliotti²⁹, Sidney Soares de Souza³⁰, Emilia Cavillon³¹, Analia Bohr³², Andrea Smichowski³³, Daniela Vidal³⁴, Dora Pereira³⁵, Liliana Martinez³⁶, Luis Somma³⁷, Marta Zalazar³⁸, Pablo Finucci Curi³⁹, Leandro Carlevaris⁴⁰, Guillermo Berbotto⁴¹ and Veronica Saurit⁴, ¹Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ²Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ³Rheumatology, Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ⁴Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ⁵Sociedad Argentina de Reumatología, CABA, Argentina, ⁶Sociedad Argentina de Reumatologia, CABA, Argentina, ⁷Sociedad Argentina de Reumatología, Buenos Aires, Argentina, ⁸SAR, CABA, Argentina, ⁹IREP, CABA, Argentina, ¹⁰Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹¹Centro Integral Reumatológico, Tucuman, Argentina, ¹²Sanatorio Parque, Cordoba, Argentina, ¹³Hospital Tornú, CABA, Argentina, ¹⁴Rheumatology Unit, Hospital Britanico de Buenos Aires, CABA, Argentina, ¹⁵Rheumatology, Sanatorio Allende de Córdoba, Cordoba, Argentina, ¹⁶Hospital Penna, Bahía Blanca, Argentina, ¹⁷Centro Platense de Reumatología, La Plata, Argentina, ¹⁸Hospital Clínica José de San Martín, CABA, Argentina, ¹⁹Hospital Cesar Milstein, CABA, Argentina, ²⁰Hospital Provincial, Rosario, Argentina, ²¹Sanatorio Parque, Rosario, Argentina, ²²Córdoba, Hospital Nacional de Clínicas, Córdoba, Argentina, ²³Hospital Bernardino Rivadavia, CABA, Argentina, ²⁴Hospital San Martín, LaPlata, Argentina, ²⁵Consultorios, Bahia Blanca, Argentina, ²⁶Hospital Zonal Bariloche, Bariloche, Argentina, ²⁷Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina, ²⁸Sanatorio Pasteur, Catamarca, Argentina, ²⁹Hospital de Niños Dr Orlando Alasia, Santa Fé, Argentina, ³⁰Ramallo 1851, REUMAR, CABA, Argentina, ³¹Consultorio, Cordoba, Argentina, ³²Hospital de Rehabilitación Rocca, CABA, Argentina, ³³Atención Integral de Reumatología, CABA, Argentina, ³⁴Hospital de Niños de Córdoba, Córdoba, Argentina, ³⁵Centro Raquis, Buenos Aires, Argentina, ³⁶Hospital Fernandez, CABA, Argentina, ³⁷SOMMA, Buenos Aires, Argentina, ³⁸Hospital Pirovano, CABA, Argentina, ³⁹Centro Médico Mitre, Entre Rios, Argentina, ⁴⁰IARI, CABA, Argentina, ⁴¹Sanatorio Británico, Rosario, Argentina
Background/Purpose: to analyze failure predictors to anti-tumor necrosis (TNF) therapy in patients who have switched these drugs during chronic arthritis treatment. Methods: BIOBADASAR is a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].